181 related articles for article (PubMed ID: 23762372)
1. Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
Bieńkowski M; Piaskowski S; Stoczyńska-Fidelus E; Szybka M; Banaszczyk M; Witusik-Perkowska M; Jesień-Lewandowicz E; Jaskólski DJ; Radomiak-Załuska A; Jesionek-Kupnicka D; Sikorska B; Papierz W; Rieske P; Liberski PP
PLoS One; 2013; 8(6):e65444. PubMed ID: 23762372
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent prognostic effects of genetic alterations in glioblastoma.
Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
[TBL] [Abstract][Full Text] [Related]
3. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
4. Genetic analyses for predictors of radiation response in glioblastoma.
Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
[TBL] [Abstract][Full Text] [Related]
5. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Lee M; Kang SY; Suh YL
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
[TBL] [Abstract][Full Text] [Related]
7. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.
Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG
J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of molecular biomarkers in glioblastoma.
Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
Zhao HF; Zhou XM; Wang J; Chen FF; Wu CP; Diao PY; Cai LR; Chen L; Xu YW; Liu J; Li ZY; Liu WL; Chen ZP; Huang GD; Li WP
J Transl Med; 2021 Aug; 19(1):372. PubMed ID: 34461927
[TBL] [Abstract][Full Text] [Related]
10. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.
Lopez-Gines C; Cerda-Nicolas M; Gil-Benso R; Pellin A; Lopez-Guerrero JA; Callaghan R; Benito R; Roldan P; Piquer J; Llacer J; Barbera J
Clin Neuropathol; 2005; 24(5):209-18. PubMed ID: 16167544
[TBL] [Abstract][Full Text] [Related]
11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
12. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
14. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
15. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
16. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
17. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
[TBL] [Abstract][Full Text] [Related]
20. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
